CStone Pharmaceuticals (stock code: 2359) announced that, according to the 2022 H Share Reward Trust Plan, 24 selected independent participants have been further granted 218,651 shares of reward shares, accounting for approximately 0.0565% of the total H shares issued and approximately 0.0075% of the total issued shares. The trust will purchase the reward shares through market transactions based on the company's instructions, without issuing new shares, and thus will not dilute the existing shareholder equity. The condition for granting rewards is that the Group's full-year revenue in 2022 will increase by no less than 68% year-on-year, which has been met. The attribution date of the reward shares is divided into four stages, which are the first trading day after the one-to-four-year anniversary of the selected participant's employment with a group member company. The announcement date of this reward plan is June 24, 2024.

CStone Pharmaceuticals (stock code: 2359) announced that, according to the 2022 H Share Reward Trust Plan, 24 selected independent participants have been further granted 218,651 shares of reward shares, accounting for approximately 0.0565% of the total H shares issued and approximately 0.0075% of the total issued shares. The trust will purchase the reward shares through market transactions based on the company's instructions, without issuing new shares, and thus will not dilute the existing shareholder equity. The condition for granting rewards is that the Group's full-year revenue in 2022 will increase by no less than 68% year-on-year, which has been met. The attribution date of the reward shares is divided into four stages, which are the first trading day after the one-to-four-year anniversary of the selected participant's employment with a group member company. The announcement date of this reward plan is June 24, 2024.